FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

Teva gets patent for invention related to MS drug





























The company claims that the pharmaceutical composition in the product, related to multiple sclerosis drug Nerventra (Laquinimod), provides a superior stabilisation effect

Israel-based Teva Pharmaceuticals has received a patent approval for its invention related to multiple sclerosis drug Laquinimod. According to reports, Laquinimod is developed by Teva Pharma in collaboration with Active Biotech AB, a Swedish biotechnology company which has focus on neurodegenerative/inflammatory diseases and cancer.

According to Active Biotech, laquinimod is a compound under development for the treatment of multiple sclerosis and Huntington’s disease and the company has an agreement with Teva covering the development and commercialisation of the drug.

The patent application, titled Stable Laquinimod Preparations, is for a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt of it and meglumine and a pharmacuetically acceptable carrier. The company claims that it has unexpectedly found that this pharmaceutical composition provides a superior stabilisation effect. It has also amended some of the claims to include the ratio range of the ingredients used in the composition, in order to address the objections raised by the examiner of Patent Office.

The objections of patent office include that the claims were mere new forms of the known compound and do not differ significantly in properties with regard to efficacy, thus falling within the scope of section 3(d) of the Patent Act 1970 as amended in 2005. Following submissions by the company addressing these objections, along with the amended set of claims the Assistant Controller of Patents and Design said that the Controller is satisfied that the application comply with the requirements of the Act as per the objections raised with respect to the hearing notice, and issued an order to proceed with the application for grant as per the amended set of claims containing 30 claims. The subject invention provides a pharmaceutical composition for use in the treatment of, or alleviation of symptoms of, a form of multiple sclerosis, claims the company.

Story Source: The above story is based on materials provided by BUSINESSSTANDARD
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News